ClinicalTrials.gg
CompletedNCT05112419Updated Jan 27, 2022

A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal Impairment

A Phase 1 interventional study of Zibotentan in Hepatic Impairment and Renal Impairment, sponsored by AstraZeneca. Completed at 1 site in Bulgaria. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-01-27.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Renal Insufficiency by AstraZeneca — none open to participants now, none under way, none of them phase 3. Renal Insufficiency · AstraZeneca.

Enrollment
25th of 29
12 · median 24
Started
2021
with 1 other
Phase 1
26 of 29
none open now
Registered
20th of 29
by date

Among the 29 studies in Renal Insufficiency by AstraZeneca, this one is the 25th largest by enrollment, is one of 2 that started in 2021, is one of 26 in phase 1, and was the 20th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 29 studies in Renal Insufficiency by AstraZeneca is open now. The open studies under Renal Insufficiency, anywhere →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 29 studies in Renal Insufficiency by AstraZeneca as a file.
02

Study summary

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a single oral dose of zibotentan in patients with moderate hepatic and moderate renal impairment in comparison to a matched healthy control group.

Read the detailed description

This is a single-dose, non-randomised, open-label, parallel-group study.

All participants will receive a single oral dose of 5 mg zibotentan under fasted conditions and will be involved in the study for approximately 5 weeks.

Approximately 12 participants will be enrolled into each one of the 2 cohorts and receive the study intervention:

  • Cohort 1: 12 participants with moderate hepatic impairment and moderate renal impairment as assessed at Screening
  • Cohort 2: 12 healthy participants matched for age (± 10 years), gender, and BMI (± 20%) on a group level to participants in Cohort 1

The study will comprise of the following study periods:

  • A Screening Period of maximum 28 days (before dosing): participants will be screened for eligibility.
  • A Residential Period of 8 days: participants will be admitted to the study centre in the evening on Day
  • 2, two days before administration of a single oral dose of zibotentan (Day 1). Participants will have final study assessments on Day 6 (120 hours post-dose) and will be discharged that day.
03

Conditions studied

  • Hepatic Impairment
  • Renal Impairment

Browse trials for

Keywords

  • Renal Impairment
  • Hepatic Impairment
  • Healthy participants
  • Zibotentan
  • Pharmacokinetics
  • Safety
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of at least 50 kg and within the range of 18 and 35 kg/m\^2 (inclusive).
  • Female of non- or male

Participants with Moderate Hepatic Impairment and Moderate Renal Impairment only (Cohort 1)

  • An estimated (eGFR) in the range of 30 to 45 mL/min/1.73m\^2 (inclusive) as determined using the Chronic Kidney Disease Epidemiology Collaboration formula, at Screening. Retesting for eGFR may be repeated twice during Screening Period.
  • Confirmed clinical diagnosis of cirrhosis with either ascites or moderate hepatic impairment (Childs-Pugh B). Supporting documents confirming the participant's hepatic impairment must be available. The participant must be classified by the Investigator or usual practitioner as Class B or having radiographic or clinical evidence of ascites of any grade.
  • Stable hepatic impairment (eg, no change in signs, symptoms, or laboratory parameters of hepatic disease status within 28 days prior to Screening, as determined by the Investigator or usual practitioner).

Healthy Participants only (Cohort 2)

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and clinical laboratory tests.
  • An eGFR of ≥ 90 mL/min/1.73m\^2 as determined using the CKD-EPI formula at Screening.
  • No clinically significant liver or kidney disease as judged by the Investigator.

Exclusion criteria

Exclusion Criteria:

Medical Conditions

  • Any evidence of a disease which in the Investigator's opinion makes it undesirable for the participant to participate in the study.
  • History of alcohol abuse or excessive intake of alcohol within 6 months prior to the Screening visit. Definition of excessive intake: an average weekly intake of >7 drinks/week for men or > 3.5 drinks/week for women. One drink is equivalent to (16 g of alcohol).
  • Positive alcohol or drug of abuse at Screening.
  • Participants with a history of severe allergy/ or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator, to drugs with a similar chemical structure or class to zibotentan.
  • Participants with known hypersensitivity/allergic reaction to paracetamol.
  • Any signs or confirmation of coronavirus disease-19 infection.

Participants with Moderate Hepatic Impairment and Moderate Renal Impairment only (Cohort 1)

  • Presence of unstable medical (eg, diabetes, epilepsy) or psychological conditions which, in the opinion of the Investigator, would compromise the participant's safety or successful participation in this study.
  • Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within 28 days prior to dosing (eg, infection of ascites, fever, or active gastrointestinal bleeding).
  • Severe hepatic impairment ( Class C Hepatic impairment), an isolated (AST) or alanine aminotransferase (ALT)> 5 x the (ULN); or total > 2 x ULN at time of enrolment or a concurrent increased AST and ALT of > 3 x the ULN together with a total bilirubin of > 2 x ULN. An isolated increase in bilirubin in participants with known Gilbert's syndrome is not a reason for exclusion.
  • Acute liver disease caused by drug toxicity or by an infection.
  • Presence of a hepatocellular carcinoma.
  • Liver or renal transplantation or planned within the next 3 months at Screening.
  • Receiving renal replacement therapy.
  • Recent acute or subacute renal function deterioration (eg, participants with large fluctuations of creatinine values, as judged by the Investigator, and documented within 28 days prior to Screening).
  • functional heart failure Class III or intravenous or with unstable heart failure requiring hospitalisation for optimisation of heart failure treatment and who are not yet stable on heart failure therapy within 6 months prior to Screening.
  • Abnormal resting vital signs (after resting for 10 minutes) of supine systolic blood pressure> 180 mmHg or \< 100 Hg; or diastolic blood pressure> 110 mmHg or \< 50 mmHg.
  • Change in dose regimen of medically-required medication within the 14 days before dosing.

Healthy Participants only (Cohort 2)

  • History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.

Prior/Concomitant Therapy

  • Use of strong or moderate inhibitors or inducers of within 28 days prior to dose of zibotentan.
  • Use of phosphate binders (eg, aluminium hydroxide and calcium carbonate) and acid reducing agents such as cholestyramine/colestipol, ranitidine/nizatidine, or proton pump inhibitors within 3 days before and 12 hours after dosing with zibotentan.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Cohort 1: Participants with moderate hepatic impairment and moderate renal impairment

    Participants will receive a single oral dose of zibotentan under fasted conditions.

    Drug: Zibotentan

  • Experimental
    Cohort 2: Healthy participants

    Participants will receive a single oral dose of zibotentan under fasted conditions.

    Drug: Zibotentan

Interventions

  • All participants will receive a single oral dose of zibotentan capsule under fasted conditions.

06

What researchers measure

Primary outcomes

  1. Area under plasma concentration-time curve from time zero to infinity (AUCinf)

    To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls

    Time frame: Day 1 to Day 6

  2. Area under the plasma concentration-curve from time zero to time of last quantifiable concentration (AUClast)

    To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls

    Time frame: Day 1 to Day 6

  3. Maximum observed plasma concentration (Cmax)

    To assess the PK of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls

    Time frame: Day 1 to Day 6

Secondary outcomes

  1. Number of participants with adverse events

    To evaluate the safety and tolerability of a single oral dose of zibotentan in participants with moderate hepatic impairment and moderate renal impairment compared to a group of healthy matched controls

    Time frame: Screening (Day -28 to Day -2) to Day 6

  2. Time to reach maximum observed plasma concentration (tmax)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  3. Area under the plasma concentration-time curve from time zero to 24 hours post-dose (AUC[0-24])

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  4. Area under plasma concentration-time curve from time zero to 72 hours post-dose (AUC [0-72])

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  5. Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  6. Terminal elimination rate constant (λz)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  7. Apparent total body clearance of drug from plasma after extravascular administration (CL/F)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  8. Apparent total non-renal body clearance of drug from plasma after extravascular administration (CLNR/F)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  9. Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)

    To further characterise zibotentan plasma PK in all treatment groups

    Time frame: Day 1 to Day 6

  10. Amount of unchanged drug excreted into urine from time t1 to time t2 [Ae (t1-t2)]

    To further characterise zibotentan urine PK in all treatment groups

    Time frame: Day 1 to Day 3

  11. Cumulative amount of unchanged drug excreted into urine from time of dosing (time 0) through time t [Ae (0-t)]

    To further characterise zibotentan urine PK in all treatment groups

    Time frame: Day 1 to Day 3

  12. Percentage of dose excreted unchanged in urine from time t1 to time t2 [fe (t1-t2)]

    To further characterise zibotentan urine PK in all treatment groups

    Time frame: Day 1 to Day 3

  13. Percentage of dose excreted unchanged in urine from time of dosing (time 0) through time t [fe (0-t)]

    To further characterise zibotentan urine PK in all treatment groups

    Time frame: Day 1 to Day 3

  14. Renal clearance of drug from plasma, calculated as Ae0-t/AUC0-t where t is matched for urine and plasma (CLR)

    To further characterise zibotentan urine PK in all treatment groups

    Time frame: Day 1 to Day 3

07

Study locations

1 site
  • Research Site
    Sofia, 1612, Bulgaria
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Dec 2021, 1 month.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 1 month is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Nov 8, 2021
StartActual
Nov 10, 2021
Primary completionActual
Dec 15, 2021
CompletionActual
Dec 15, 2021
Last update
Jan 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05112419
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Nov 10, 2021
Primary completion
Dec 15, 2021
Completion
Dec 15, 2021
Last update
Jan 27, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZD4054

Start the discussion